Antibodies against transforming growth factor-beta 1 suppress intimal hyperplasia in a rat model.

YG Wolf, LM Rasmussen… - The Journal of clinical …, 1994 - Am Soc Clin Investig
YG Wolf, LM Rasmussen, E Ruoslahti
The Journal of clinical investigation, 1994Am Soc Clin Investig
Intimal hyperplasia is induced by therapeutic vascular interventions and often results in
clinically important narrowing of the vascular lumen. Examination of the role of TGF-beta 1 in
a rat carotid artery injury model confirmed the presence of a previously reported increase in
TGF-beta 1 mRNA in the media of injured arteries. Administration of neutralizing anti-TGF-
beta 1 antibodies significantly (P< 0.05) reduced the size of the intimal lesions that
developed after carotid balloon injury. A control antibody had no effect. The intimal/medial …
Intimal hyperplasia is induced by therapeutic vascular interventions and often results in clinically important narrowing of the vascular lumen. Examination of the role of TGF-beta 1 in a rat carotid artery injury model confirmed the presence of a previously reported increase in TGF-beta 1 mRNA in the media of injured arteries. Administration of neutralizing anti- TGF-beta 1 antibodies significantly (P < 0.05) reduced the size of the intimal lesions that developed after carotid balloon injury. A control antibody had no effect. The intimal/medial area ratio was also reduced in the anti-TGF-beta 1 group relative to controls (P < 0.01). Immunohistochemical staining showed that two TGF-beta 1-induced extracellular matrix components, EDA + fibronectin and versican, were greatly increased in the untreated neointimal lesions, but were almost completely absent from the lesions of the anti-TGF-beta 1-treated animals. We conclude that TGF-beta 1 is causally involved in the development of intimal hyperplasia, and that anti-TGF-beta 1 agents may be useful in achieving at least partial control of this condition.
Images
The Journal of Clinical Investigation